Cytomegalovirus-based vaccine expressing ebola virus glycoprotein
AssigneesUniversity of Plymouth, The Regents of the University of California
InventorsMichael Arthur JARVIS, Aisling Aoife MURPHY, Heinrich FELDMANN, Andrea Marzi, Ilhem Messaoudi Powers
Life of this patent
Estimating the term…
Abstract
A recombinant herpesvirus-based vector comprising a nucleic acid sequence encoding a heterologous antigen and a promoter for controlling the expression of the antigen, in which the promoter is expressed at a time selected to provide a required immune response in a subject.
Claims22
1-44. (canceled)
Use of a recombinant herpesvirus-based vector to provide an immune response in a subject which is biased towards an antibody response, the vector comprising a nucleic acid sequence encoding a heterologous antigen and a promoter for controlling the expression of the antigen, in which the promoter is expressed at L times.
A method of preventing or treating an infectious disease by providing an immune response in a subject which is biased towards an antibody cell response, the method comprising administration of a recombinant herpesvirus-based vector, the vector comprising a nucleic acid sequence encoding a heterologous antigen and a promoter for controlling the expression of the antigen, in which the promoter is expressed at L times.
A method of preparing a recombinant herpesvirus-based vector comprising the steps of:
- providing a nucleic acid sequence encoding a heterologous antigen;
- selecting a promoter for controlling the expression of the antigen,
- in which the promoter is selected to express at a time selected to provide a required immune response in a subject selected from the group consisting of:
- T-cell biased;
- antibody biased;
- balanced T-cell and antibody.
Dependencies are inferred from the claim text.